HIV Policy & Advocacy
CROI 2013: Small Risk of Birth Defects Due to Efavirenz Confirmed in French Cohort
- Details
- Category: HIV Treatment
- Published on Wednesday, 20 March 2013 00:00
- Written by Keith Alcorn
A large French study has found an elevated risk of some birth defects in children born to women exposed to some antiretroviral drugs during the first trimester of pregnancy, French researchers reported on at the 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013) this month in Atlanta.
CROI 2013: HIV+ People Less Likely to Use Aspirin to Prevent Heart Attacks, and May Benefit Less [VIDEO]
- Details
- Category: HIV-Related Conditions
- Published on Friday, 15 March 2013 00:00
- Written by Gregory Fowler
People with HIV were less likely than HIV negative people to use daily aspirin to prevent heart attacks, but among those who did, aspirin did not appear to reduce the risk of myocardial infarction (MI), researchers reported last week at the 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013) in Atlanta.
CROI 2013: Can People with Resistant HIV Omit NRTIs When Switching to a New Regimen? [VIDEO]
- Details
- Category: HIV Treatment
- Published on Thursday, 07 March 2013 00:00
- Written by Liz Highleyman
Omitting nucleoside reverse transcriptase inhibitors (NRTIs) when switching from a non-suppressive regimen to a new combination with at least 2 active agents can reduce pill burden and side effects without compromising effectiveness, researchers reported yesterday at the 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013) in Atlanta.
CROI 2013: New Pro-drug Tenofovir Alafenamide Appears Equally Effective but Better Tolerated
- Details
- Category: HIV Treatment
- Published on Thursday, 07 March 2013 00:00
- Written by Liz Highleyman
Tenofovir alafenamide fumarate, or TAF (formerly GS-7340), a new pro-drug of the widely used NRTI tenofovir, reaches cells harboring HIV more easily than the older disoproxil fumarate (TDF), allowing for similar antiviral efficacy with smaller doses and with less adverse effect on kidneys and bones,researchers reported Tuesday at the 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013) in Atlanta.
CROI 2013: New Tenofovir Alafenamide Looks Easier on Kidneys [VIDEO]
- Details
- Category: HIV Treatment
- Published on Wednesday, 06 March 2013 00:00
- Written by Gregory Fowler
A new pro-drug formulation of the widely used nucleotide reverse transcriptase inhibitor analog tenofovir (Viread, also in the Truvada, Atripla, Complera, and Stribild combination pills) worked as well as the existing formulation, but appears to have less potential for kidney and bone toxicity, according to a presentation Tuesday at the 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013) in Atlanta.
More Articles...
- CROI 2013: Pipeline Antiretrovirals Promise More Effective and Better Tolerated HIV Treatment
- CROI 2013: Health Insurance Coverage Linked to HIV Viral Load Suppression [VIDEO]
- President's HIV/AIDS Council Responds to Unjust HIV Criminalization Laws
- Generic HIV Drugs Could Save Millions, But May Reduce Effectiveness
Web Design and Development by